Arcus Biosciences Announces New Employment Inducement Grants

Audio By Carbonatix

HAYWARD, Calif.--(BUSINESS WIRE)--May 27, 2025--

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 13,400 shares of the Company’s common stock at an exercise price per share of $9.02, which was the closing price on May 23, 2025, and restricted stock units to acquire a total of 13,400 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a, CD73, A2a/A2b receptors, CD39 and AXL. For more information about Arcus Biosciences’s clinical and preclinical programs, please visit www.arcusbio.com.

Inducement PR

Source: Arcus Biosciences

View source version on businesswire.com:https://www.businesswire.com/news/home/20250527964946/en/

CONTACT: Investor Inquiries:

Pia Eaves

VP of Investor Relations & Strategy

(617) 459-2006

[email protected] Inquiries:

Holli Kolkey

VP of Corporate Communications

(650) 922-1269

[email protected] Bassiri

AD, Corporate Communications

(510) 406-8520

[email protected]

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICAL CLINICAL TRIALS ONCOLOGY

SOURCE: Arcus Biosciences

Copyright Business Wire 2025.

PUB: 05/27/2025 04:35 PM/DISC: 05/27/2025 04:34 PM

http://www.businesswire.com/news/home/20250527964946/en